Lumida
/CBLL
⌘K
Ceribell Inc

Ceribell Inc

CBLL
$23.63USD+0.85%+0.20 today

MARKET CAP

906.9M

P/E (TTM)

FWD P/E

DAY RANGE

$23 – $24

52W RANGE

$11
$25

AI Summary

Stalk
Buy NowMedium

CBLL remains in a medium-term bullish Stage 2 advance, driven by an accelerating parabola structure. Price is holding just above the rising 9-day EMA after a shallow pullback, with EMAs stacked and momentum intact. RSI has eased from extreme overbought, suggesting room for consolidation or renewed upside. The path of least resistance remains higher, favoring entries near EMA support.

  • CBLL leads neurological diagnostics with digital health market tailwinds
  • 1.62% dividend yield appeals to income-oriented investors
  • EPS fell short of estimates, causing a 0.8% share decline
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$65.4M$89.1M
YoY %+36.1%
P / Sales4.7x9.0x
EV / Sales2.3x9.0x
Gross Profit, Adj.$56.8M$78.3M
YoY %+37.9%
Margin %86.7%87.9%
EV / Gross Profit2.6x10.2x
EBITDA, Adj.$-38.6M$-57.1M
YoY %-47.9%
Margin %-58.9%-64.1%
EV / EBITDA-3.9x-14.0x
EBIT$-39.7M$-58.4M
YoY %-47.1%
Margin %-60.7%-65.6%
EV / EBIT-3.8x-13.7x
Net Income$-40.5M$-53.4M
YoY %-32.0%
Net Margin-61.8%-60.0%
EPS (GAAP)-$3.39-$1.46
YoY %+56.9%